title: A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia.
authors.affiliation: Mahidol University, Bangkok, Thailand.
authors.forename: Poramin
authors.initials: P
authors.lastname: Patthamalai
authors.forename: Suthat
authors.initials: S
authors.lastname: Fuchareon
authors.forename: Nattawara
authors.initials: N
authors.lastname: Chaneiam
authors.forename: Richard G
authors.initials: RG
authors.lastname: Ghalie
authors.forename: David H K
authors.initials: DH
authors.lastname: Chui
authors.forename: Michael S
authors.initials: MS
authors.lastname: Boosalis
authors.forename: Susan P
authors.initials: SP
authors.lastname: Perrine
mesh_terms: D000328:Adult; D002087:Butyrates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005319:Fetal Hemoglobin / Q000096:biosynthesis*; D006446:Hemoglobin E / Q000235:genetics*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008297:Male; D055815:Young Adult; D017086:beta-Thalassemia / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics
chemical_list: D002087:Butyrates; D006454:Hemoglobins; D006446:Hemoglobin E; D005319:Fetal Hemoglobin; C074677:2,2-dimethylbutyric acid